ReviewWorld journal of gastroenterology2021
New hope for hepatitis C virus: Summary of global epidemiologic changes and novel innovations over 20 years.
Review in World journal of gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Population-based prevalence and screening gaps of hepatitis C, B and D, Germany, 2020 to 2021.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Article
- All-cause mortality and overdose deaths among 4192 people who inject drugs in Stockholm: a 10-year register-based cohort study.Harm reduction journal · 2026Article
- HCV immunodominant peptide mapping reveals unique HLA-A*02-restricted signatures: insights for CD8Immunogenetics · 2025Article
- Health service utilization, substance use treatment response, and death in patients with opioid use disorder and comorbid hepatitis C findings from prospective cohort study with administrative database linkage.Journal of substance use and addiction treatment · 2024Article
- New perspectives in hepatocellular carcinoma surveillance after hepatitis C virus eradication.Gastroenterology report · 2024Review
- Current epidemiology of chronic liver disease.Gastroenterology report · 2024Review
- Real-world treatment outcome of direct-acting antivirals and patient survival rates in chronic hepatitis C virus infection in Eritrea.Scientific reports · 2023Observational
- Prevalence of hepatitis C virus among patients with arthralgia: is it logic for screening?Virology journal · 2023Observational
- Seroprevalence and Genotype Diversity of Hepatitis C Virus in the Caribbean-A Review.Tropical medicine and infectious disease · 2023Review
- A Comprehensive Analysis of 21 Actionable Pharmacogenes in the Spanish Population: From Genetic Characterisation to Clinical Impact.Pharmaceutics · 2023Article
- Assessing feasibility of a modified same-day test-and-treat model for hepatitis C among rural people who inject drugs.Harm reduction journal · 2023Article
- Preclinical Long-term Magnetic Resonance Imaging Study of Silymarin Liver-protective Effects.Journal of clinical and translational hepatology · 2022Article
- Hepatitis C prevalence and key population size estimate updates in San Francisco: 2015 to 2019.PloS one · 2022Article
- Alanine Aminotransferase and Bilirubin Dynamic Evolution Pattern as a Novel Model for the Prediction of Acute Liver Failure in Drug-Induced Liver Injury.Frontiers in pharmacology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C virus (HCV) is a global health concern associated with significant morbidity and mortality. Before the approval of second-generation direct-acting antiviral agents (DAAs), interferon therapy and liver transplantation constituted the mainstay of treatment. The introduction of well-tolerated oral DAAs in late 2013 has revolutionized HCV management with over 95% cure rates. The predominance of HCV-related liver transplantations has declined following the widespread approval of DAAs. Despite the unparallel efficacy observed among these novel therapies, pharmaceutical costs continue to limit equitable access to healthcare and likely contribute to the differential HCV infection rates observed globally. To reduce the burden of disease worldwide, essential agenda items for all countries must include the prioritization of integrated care models and access to DAAs therapies. Through transparent negotiations with the pharmaceutical industry, the consideration for compassionate release of medications to promote equitable division of care is paramount. Here we provide a literature review of HCV, changes in epidemiologic trends, access issues for current therapies, and global inequities in disease burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.